Showing results (151-160 of 179) with videos related to

Sort By:
Pageof 18
Horticulture Research|December 6, 2016
Towards an open grapevine information systemA-F Adam-Blondon, M Alaux, C Pommier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2019
Pathologic Considerations and Standardization in Mesothelioma Clinical TrialsMing-Sound Tsao, Michele Carbone, Francoise Galateau-Salle, et al.
Investigational New Drugs|May 9, 2019
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesotheliomaEmilie M J van Brummelen, Evgeny Levchenko, Manuel Dómine, et al.
The Lancet. Respiratory Medicine|May 20, 2019
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trialGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
Frontiers in Endocrinology|March 14, 2019
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?Anne-Marie Baird, David Easty, Monika Jarzabek, et al.
Nature Communications|July 14, 2026
Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancerVictoria Gibson, Joanna Dzialo, Terri Messier, et al.
The Lancet. Oncology|March 31, 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trialHedy L Kindler, Silvia Novello, Alessandra Bearz, et al.
Elife|January 19, 2018
Loss of functional BAP1 augments sensitivity to TRAIL in cancer cellsKrishna Kalyan Kolluri, Constantine Alifrangis, Neelam Kumar, et al.
Cancer Cell|September 30, 2022
Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responsesKah Lok Chan, Juliana Gomez, Chelisa Cardinez, et al.
Pageof 18